CPT Pharmacometrics & Systems Pharmacology · 2019 · 10 citations · 38 references
PharmacyPharmacokineticsPharmacologyBioavailabilityHepatic PharmacokineticsPharmacokinetic ModelingDrug DispositionHepatic Drug MetabolismLiver RegenerationLiver TransplantationPhysiologically Based Pharmacokinetic ModelingTransplant PharmacokineticsAdult Liver TransplantationCyp3a5 Genotype EffectsCyp3a5 PharmacogeneticsCytochrome P450 GenotypingOral Drug ClearanceTacrolimus PharmacogeneticsTacrolimus PharmacokineticsTacrolimus Therapy
In adult patients after living-donor liver transplantation, postoperative days and the cytochrome P450 3A5 (CYP3A5) genotype are known to affect tacrolimus pharmacokinetics. In this study, we constructed a physiologically-based pharmacokinetic model adapted to the clinical data and evaluated the contribution of liver regeneration as well as hepatic and intestine CYP3A5 genotypes on tacrolimus pharmacokinetics. As a result, liver function recovered immediately and affected the total body clearance of tacrolimus only during a limited period after living-donor liver transplantation. The clearance was about 1.35-fold higher in the recipients who had a liver with the CYP3A5*1 allele than in those with the CYP3A5*3/*3 genotype, whereas bioavailability was ~0.7-fold higher in the recipients who had intestines with the CYP3A5*1 allele than those with CYP3A5*3/*3. In conclusion, the constructed physiologically-based pharmacokinetic model clarified that the oral clearance of tacrolimus was affected by the CYP3A5 genotypes in both the liver and intestine to the same extent.
38